U were preparing a file for me then I pressed something by mistake and it’s gone

Browsing Directory

Good news - the file is still there and intact! Nothing was lost. Here it is:

Hypopharynx Cancer ENT Exam

PDF Document · PDF

You can download it directly from that link. All the supporting files (diagrams, images, the build script) are also still in place. Whatever you pressed didn't delete anything on my end - the workspace persists independently of your browser session.

It’s empty

Running Command

Reading File

Running Command

Rebuilt successfully. Try downloading it again:

Hypopharynx Cancer ENT Exam

PDF Document · PDF

The file is 5.4 MB. If it still appears empty when you open it, the issue may be with your PDF viewer - try opening it in a different app (browser, Adobe Reader, etc.).

Can’t download now

That's likely a temporary session/connectivity issue. A few things to try:

Refresh the page - then try the download link again
Right-click the link and choose "Save link as..."
Try a different browser if the current one is acting up

The file is fully intact on my end (5.4 MB, freshly rebuilt). As soon as your session is stable, the link will work:

Hypopharynx Cancer ENT Exam

PDF Document · PDF

If none of that works, let me know and I can try an alternative delivery method (e.g. convert it to a different format, or share the content as text).

Nup it’s just 45 bytes

Asking for Preferences

Reading File

Running Command

Here is the full content of your exam answer. You can copy everything below:

CARCINOMA OF THE HYPOPHARYNX

University Examination Answer - 20 Marks Department of Otorhinolaryngology - Head & Neck Surgery | 3rd Year MD/MS Residency Programme Date: June 2026 | Marks: 20 | Expected Length: 15-20 pages

Sources: Cummings Otolaryngology 7th Ed. | Scott-Brown's ORL | KJ Lee's Essential Otolaryngology 11th Ed. | Shambaugh Surgery of the Ear | PubMed Meta-analyses & Systematic Reviews 2022-2025

1. INTRODUCTION & DEFINITION

Carcinoma of the hypopharynx is one of the most challenging and lethal malignancies of the upper aerodigestive tract. It carries the worst prognosis among all head and neck cancers, primarily because the majority of patients present at an advanced stage (Stage III/IV), when the disease is either locally advanced, involves the larynx, or has already metastasised to regional cervical lymph nodes. The insidious nature of the hypopharynx - a structure largely silent in early disease - and the rich submucosal lymphatic network account for this.

Historically, treatment involved radical extirpation with total laryngopharyngectomy. Contemporary management has evolved toward organ-preservation strategies using concurrent chemoradiotherapy (CCRT), transoral laser microsurgery (TLM), and transoral robotic surgery (TORS) for selected patients - though organ-preservation rates remain significantly lower in hypopharyngeal carcinoma than in laryngeal carcinoma. (Cummings, 7th Ed.)

2. SURGICAL ANATOMY OF THE HYPOPHARYNX

A thorough knowledge of hypopharyngeal anatomy is essential to understanding patterns of tumour spread, lymphatic drainage, and selection of surgical approach.

Boundaries:

Superior: Level of the vallecular floor / superior aspect of the hyoid bone
Inferior: Lower border of the cricoid cartilage (C6 level) - continuation into cervical oesophagus
Anterior: Posterior aspect of the larynx (arytenoids, cricoid)
Posterior: Prevertebral fascia (C3-C6 vertebrae)

2.1 Subsites (AJCC/UICC Classification)

Piriform Sinus (Pyriform Fossa) - 60-70% of hypopharyngeal carcinomas

Paired, funnel-shaped recesses flanking the larynx bilaterally
Medial wall: aryepiglottic fold and arytenoid cartilage
Lateral wall: thyroid cartilage and thyrohyoid membrane
Apex: at the level of the inferior border of the cricoid
Rich submucosal spread - tumours extend submucosally beyond visible margin
Poorest prognosis due to early nodal metastasis and propensity for apex involvement

Postcricoid Region - 5-15% of all hypopharyngeal cancers

Anterior wall of the hypopharynx, posterior surface of the cricoid and arytenoid cartilages
Strongly associated with Plummer-Vinson (Patterson-Kelly-Brown) syndrome
Predominantly affects women in 4th-5th decade
Tendency for circumferential spread and early oesophageal involvement

Posterior Pharyngeal Wall

Extends from the level of the hyoid superiorly to the pharyngo-oesophageal junction
Spread tends to be superficial and along the mucosal surface
Posterior extension to prevertebral fascia dramatically worsens prognosis
Invasion of prevertebral fascia = T4b = unresectable

2.2 Relations of Clinical Importance

Medial piriform sinus tumours: spread to arytenoid, cricoarytenoid joint → vocal cord fixation
Lateral piriform sinus tumours: thyroid cartilage, paraglottic fat, thyrohyoid membrane
Apex of piriform sinus tumours: thyroarytenoid space, cervical oesophagus
Posterior wall tumours: prevertebral fascia (T4b if invaded), retropharyngeal nodes
Postcricoid tumours: oesophageal inlet, posterior cricoarytenoid muscles → cord paralysis

2.3 Lymphatic Drainage

The hypopharynx has an extensive and often bilateral lymphatic drainage. This accounts for the high rate of cervical nodal metastasis (60-80% at presentation) and frequent contralateral nodal spread.

Piriform sinus: Levels II, III, IV (ipsilateral); retropharyngeal, Level V, contralateral II-IV
Postcricoid: Levels II, III, IV bilateral
Posterior wall: Retropharyngeal nodes, Level II-IV; bilateral Level II-IV, Level V

3. EPIDEMIOLOGY & AETIOLOGY

Accounts for 3-5% of all head and neck malignancies
Peak incidence: 5th-7th decade of life
Male:Female = 3-4:1 overall; postcricoid carcinoma more common in females
Higher incidence in parts of Scandinavia, India, South-East Asia
5-year overall survival: 25-35% (Stage I/II ~60%; Stage III/IV ~15-25%)
Distant metastasis present in 10-20% at diagnosis

3.1 Aetiology & Risk Factors

A. Tobacco and Alcohol (Dominant Risk Factors)

Tobacco smoking: strongest risk factor - dose-dependent and synergistic with alcohol
Heavy alcohol consumption: independent risk factor; acts synergistically with tobacco
Combined tobacco + alcohol use increases risk 30-100 fold compared to non-users
Risk persists for years after cessation but gradually declines

B. Plummer-Vinson (Paterson-Kelly-Brown) Syndrome

Classically associated with postcricoid carcinoma. Clinical triad:
- Iron-deficiency anaemia (hypochromic, microcytic)
- Dysphagia (due to postcricoid web / mucosal atrophy)
- Glossitis, angular stomatitis, koilonychia
The postcricoid web is considered a premalignant lesion. Iron supplementation may cause regression of the web but the cancer risk remains elevated. Predominantly affects women of Northern European and Scandinavian origin. (Scott-Brown's ORL)

C. Nutritional Deficiencies

Deficiencies in iron, riboflavin, vitamin A, zinc - associated with epithelial dysplasia
Postcricoid carcinoma: particularly linked to long-standing iron deficiency

D. HPV (Human Papillomavirus)

HPV role in hypopharyngeal carcinoma is less prominent than in oropharyngeal cancer
HPV-positive hypopharyngeal carcinoma is rare; does NOT confer same survival benefit as in oropharynx
HPV-16 is the predominant subtype when detected

E. Other Factors

Gastro-oesophageal reflux disease (GORD): possible association with posterior wall carcinoma
Previous radiotherapy to the neck
Occupational exposures: asbestos, wood dust, paint fumes, nickel refining

4. PATHOLOGY

4.1 Histological Types

Squamous Cell Carcinoma (SCC): >95%; keratinising or non-keratinising; moderately differentiated most common
Adenocarcinoma: rare; arises from minor salivary glands
Undifferentiated carcinoma: nasopharynx-type; rare in hypopharynx
Lymphoma: primarily NHL; tends to present as posterior wall lesion
Sarcoma: chondrosarcoma of cricoid; rhabdomyosarcoma

4.2 Macroscopic & Microscopic Appearances

Exophytic / fungating lesion - most common in piriform sinus
Infiltrative / ulcerative pattern - common in posterior wall
Submucosal spread is pathognomonic - tumour extends well beyond visible margins
Up to 60% of cases have submucosal spread that upstages the tumour (Cummings)
Moderately differentiated SCC: most common; keratinisation present
Perineural invasion (PNI): common; associated with local recurrence
Lymphovascular invasion (LVI): present in >50%; predictor of nodal metastasis
Dysplasia at surgical margins: zero tolerance required
Field cancerisation: synchronous or metachronous tumours in 5-10% of patients

4.3 Patterns of Spread

Direct: Larynx (arytenoid, cricoid, thyroid cartilage), oesophagus, thyroid gland, prevertebral fascia
Submucosal: Occurs in 60% - spreads well beyond visible margins; responsible for understaging
Lymphatic: Levels II, III, IV (primary); retropharyngeal (posterior wall); 60-80% at presentation; bilateral 10-20%
Distant: Lungs (most common ~20%), liver, bone; M1 disease in 5-10% at diagnosis
Oesophageal skip metastasis in 5-7%; necessitates upper endoscopy for staging

5. CLINICAL FEATURES

The hypopharynx region - early carcinomas produce minimal symptoms and are easily missed. By the time symptoms are clinically significant, over 70-80% of patients already have Stage III or Stage IV disease.

5.1 Symptoms

A. Early Symptoms

Vague throat discomfort / foreign body sensation (globus pharyngis)
Mild, intermittent dysphagia - often ignored initially
Unilateral otalgia (referred pain via the auricular branch of CN X - Arnold's nerve)
Slight change in voice quality

B. Late / Advanced Symptoms

Progressive odynophagia and dysphagia - liquids and solids
Weight loss, cachexia - due to dysphagia and systemic effects of malignancy
Hoarseness - from laryngeal involvement or recurrent laryngeal nerve invasion
Stridor - from laryngeal/subglottic involvement; indicates large tumour
Aspiration pneumonia - from impaired laryngeal protective reflexes
Neck mass - palpable cervical node metastasis (often the first presenting symptom!)
Haemoptysis or haematemesis - bleeding from ulcerated tumour
Halitosis - from tumour necrosis and superadded infection

5.2 Signs on Examination

General Examination:

Pallor (anaemia - especially with Plummer-Vinson syndrome)
Cachexia, malnutrition, dehydration
Koilonychia, angular stomatitis (Plummer-Vinson)
Features of metastatic disease: hepatomegaly, bone tenderness

Head & Neck Examination:

Cervical lymphadenopathy: levels II, III, IV most common; hard, non-tender, fixed in advanced disease
Indirect laryngoscopy / flexible nasolaryngoscopy:
- Pooling of saliva in piriform fossa (sentinel sign of piriform sinus tumour)
- Ulcerated / exophytic lesion visible in hypopharynx
- Vocal cord fixation (indicates arytenoid, cricoarytenoid joint, or RLN involvement)
- Medialisation or obliteration of piriform sinus
Thyroid gland enlargement in advanced cases with direct extension
Trismus: unusual; suggests deep tissue/pterygoid involvement

5.3 Clinical Scenarios by Subsite

Piriform sinus: Otalgia + ipsilateral neck mass; pooling of saliva; late hoarseness from laryngeal invasion
Postcricoid: Progressive dysphagia in middle-aged woman with Plummer-Vinson; iron deficiency anaemia; web on barium swallow
Posterior wall: Persistent sore throat, neck stiffness, referred otalgia; prevertebral invasion detected on MRI/CT

6. INVESTIGATIONS & IMAGING

6.1 Clinical Staging - Endoscopy

Flexible fibreoptic nasolaryngoscopy: first-line assessment of primary tumour
Direct laryngoscopy and hypopharyngoscopy under GA (panendoscopy): assessment of tumour extent, biopsy for histopathological confirmation, inspection of oropharynx/larynx for synchronous lesions
Rigid oesophagoscopy: mandatory to exclude oesophageal involvement (skip lesions, Plummer-Vinson web)
Bronchoscopy: if lung involvement or tracheal invasion suspected

6.2 Imaging

Modality	Role
CT Neck + Chest (contrast)	Tumour extent, cartilage invasion, nodal metastasis, lung mets; key for T staging and resectability
MRI Neck	Superior for prevertebral fascia invasion, soft tissue planes, perineural spread, cartilage marrow involvement; best for T4b assessment
PET-CT	Gold standard for nodal staging and distant metastasis detection; identifies occult contralateral nodal disease; recommended for all hypopharyngeal cancers (Cummings)
Barium swallow	Demonstrates mucosal irregularity, web, filling defect, oesophageal involvement; postcricoid & post-wall tumours
CXR	Pulmonary metastasis, second primary lung cancer (5-7%)
FNAC	Guided fine needle aspiration cytology of suspicious nodes - confirms metastasis without open biopsy

Key point: PET-CT is recommended as initial imaging for all hypopharyngeal cancers due to the high rate of submucosal spread (up to 60%) that causes clinically undetectable upstaging. Standard CT/MRI alone significantly underestimates disease extent. (Cummings, 7th Ed.)

6.3 Laboratory Investigations

Full blood count: anaemia (Plummer-Vinson), baseline haematology
Serum iron, ferritin, TIBC: important in postcricoid carcinoma workup
Liver function tests, renal function: fitness for chemotherapy; hepatic metastasis assessment
Thyroid function tests: especially if thyroid extension or post-treatment monitoring
Serum albumin, nutritional markers: prognostic; guide need for preoperative nutritional support
HPV testing: optional; less impactful in hypopharynx than oropharynx

7. TNM STAGING - AJCC 8th EDITION (2017)

7.1 Primary Tumour (T) Staging

T	Description
TX	Primary tumour cannot be assessed
T1	Tumour limited to one subsite of hypopharynx AND ≤2 cm in greatest dimension
T2	Tumour invades more than one subsite OR an adjacent site, OR >2 cm but ≤4 cm, WITHOUT fixation of the hemilarynx
T3	Tumour measures >4 cm OR with fixation of the hemilarynx OR extension to the oesophagus
T4a	Moderately advanced: tumour invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, oesophagus, or central compartment soft tissue
T4b	Very advanced: tumour invades prevertebral fascia, encases carotid artery, or involves mediastinal structures - UNRESECTABLE

7.2 Regional Lymph Nodes (N) Staging - Clinical (cN)

N	Description
N0	No regional lymph node metastasis
N1	Single ipsilateral node ≤3 cm, ENE negative
N2a	Single ipsilateral node 3-6 cm, ENE negative
N2b	Multiple ipsilateral nodes, none >6 cm, ENE negative
N2c	Bilateral or contralateral nodes, none >6 cm, ENE negative
N3a	Any node >6 cm, ENE negative
N3b	Any node with ENE positive (clinical extranodal extension)

7.3 Overall Stage Grouping

Stage	Description
I (T1N0M0)	Limited to one subsite, ≤2 cm, no nodes
II (T2N0M0)	Multi-subsite or 2-4 cm, no nodes
III	T3N0 or T1-3 N1 - advanced local disease or single node
IVA	T4a or N2 - moderately advanced: resectable
IVB	T4b or N3 - unresectable (prevertebral invasion / carotid encasement)
IVC	Any M1 - distant metastasis present

8. PRINCIPLES OF MANAGEMENT

The management of hypopharyngeal carcinoma requires a multidisciplinary team (MDT) approach involving ENT/Head & Neck surgeons, radiation oncologists, medical oncologists, speech and language therapists, and reconstructive surgeons. No single treatment modality has demonstrated definitive superiority in randomised controlled trials, and management decisions are guided by tumour stage, subsite, patient performance status, and institutional expertise. (Cummings, 7th Ed.)

Evidence Note: A 2022 systematic review and meta-analysis of all available RCTs (Panda et al., PLoS One, PMID 36445884) found no statistically significant difference between organ-preservation and non-organ-preservation strategies in overall survival for resectable hypopharyngeal SCC. However, concurrent CRT showed superior laryngectomy-free survival (HR 0.28, 95% CI 0.13-0.57) compared to sequential chemotherapy + RT. Postoperative RT was associated with better OS than preoperative RT.

8.1 General Pretreatment Principles

Staging workup must be complete before treatment planning
Nutritional assessment mandatory - many patients are malnourished; NG/PEG feeding may be needed preoperatively
Dental evaluation and extraction before radiotherapy to prevent osteoradionecrosis
Smoking cessation counselling - active smoking during RT significantly reduces response
Hypothyroidism screening post-treatment (especially after laryngopharyngectomy or neck RT)
Speech and swallowing rehabilitation: voice prosthesis (TEP), oesophageal speech training

8.2 Treatment Overview by Stage

Stage	Treatment
T1 N0	Surgery (TLM or partial pharyngectomy) + PORT OR Definitive RT alone
T1-2 N1	CCRT for organ preservation
T2-T3 N0-N1 (Organ Preservation)	Concurrent chemoradiotherapy (CCRT); bioselective protocol: induction → RT for responders
T3-T4a N0-N2 (Advanced Resectable)	Total laryngopharyngectomy + bilateral neck dissection + PORT ± chemotherapy; CCRT if organ preservation desired
T4b or N3 ENE+ (Unresectable)	Concurrent CRT (definitive intent) ± induction chemotherapy; palliative RT / best supportive care
M1	Palliative chemotherapy (platinum + 5-FU ± cetuximab); Pembrolizumab (PD-L1+) as first-line; palliative RT, best supportive care

9. SURGICAL MANAGEMENT

9.1 Endoscopic Surgery - Transoral Approaches

A. Transoral Laser Microsurgery (TLM) Pioneered by Steiner and colleagues over >30 years. Uses CO2 laser under operating microscope with a bivalved laryngopharyngoscope. The tumour is intentionally cut through during resection to assess depth and cartilage invasion.

Indications: T1-T2 tumours; select T3 in experienced hands; no cartilage invasion through thyroid to neck
Absolute contraindication: thyroid cartilage invasion through to neck soft tissues
Advantages: no tracheostomy required; no reconstruction needed; early oral feeding (Day 1); shorter hospitalisation
Outcome (Steiner 1986-2003, n=172, T1-T4): OS 71% (Stage I/II) and 47% (Stage III/IV)
Node dissections performed separately, delayed, as indicated by tumour stage

B. Transoral Robotic Surgery (TORS)

Da Vinci robotic system provides 3D visualisation and wristed instrument articulation
Useful for hypopharyngeal tumours with anatomical access limitations
Emerging modality - growing evidence base for T1-T2 lesions
Thunderbeat system (ultrasonic + bipolar energy): recent systematic review (Saraniti et al., 2023, PMID 37014427) shows comparable outcomes

9.2 Open Surgical Procedures

A. Partial Laryngopharyngectomy (Conservation Surgery)

Suitable for carefully selected early lesions confined to one piriform sinus wall
Lateral pharyngotomy approach for posterior wall tumours
Supracricoid hemilaryngopharyngectomy: selected T2-T3 piriform sinus lesions
Near-total laryngectomy: preserves one arytenoid unit; minimal functional larynx retained

B. Total Laryngopharyngectomy (TLP) The standard operation for advanced hypopharyngeal carcinoma (T3-T4). First performed by Czerny in 1877.

Indications (Cummings, 7th Ed.):

Piriform sinus: posterior spread across postcricoid beyond midline, or oesophageal inlet involvement
Postcricoid: all except earliest lesions; especially when vocal cord paralysis present
Posterior wall: tumour extending below arytenoids anteriorly or into piriform sinuses
Any case with vocal cord fixation from cricoarytenoid joint or posterior cricoarytenoid muscle invasion

Steps of Total Laryngopharyngectomy:

Tracheostomy (usually performed first for airway security)
Apron incision + bilateral neck dissection (levels II, III, IV; ± I, V, VI as indicated)
Division of suprahyoid musculature and infrahyoid strap muscles
Thyroid gland: ipsilateral hemithyroidectomy or total thyroidectomy based on involvement
Entry into pharynx: above the tumour through vallecula or lateral to hyoid
Division of oesophagus: below the tumour, ensuring adequate distal margin
Bilateral recurrent laryngeal nerve division (inevitable with total laryngectomy)
En-bloc removal of larynx + hypopharynx ± cervical oesophagus
Frozen section margins: anterior, posterior, lateral, superior, inferior - zero tolerance for positivity
Reconstruction (see Section 11)
Permanent tracheostomy - end tracheostomy brought out at base of neck

9.3 Neck Dissection

Neck dissection is an integral part of surgical management due to the very high rate of nodal metastasis (60-80% at presentation).

N0 neck: elective selective neck dissection (levels II-IV) recommended bilaterally given >25% occult metastasis rate
N1-N2: therapeutic modified radical neck dissection (MRND) ipsilateral; elective contralateral dissection
N3 / fixed nodes: radical neck dissection; consider neoadjuvant chemotherapy first
Extranodal extension (ENE): mandates adjuvant CCRT (cisplatin-based)

Evidence: A 2024 multicenter systematic review (Deuss et al., PMID 38830380) found that for T1/T2 hypopharyngeal carcinomas, neck dissection significantly improves regional control and should not be omitted even in the clinically N0 neck.

10. NON-SURGICAL / ORGAN PRESERVATION STRATEGIES

Organ preservation in hypopharyngeal carcinoma aims to cure the patient while retaining a functioning larynx. The landmark EORTC 24891 trial established the principle of larynx preservation using induction chemotherapy followed by radiotherapy for responders.

10.1 EORTC 24891 Protocol - Landmark Trial

Induction PF (cisplatin 100 mg/m2 Day 1 + 5-FU 1000 mg/m2/day Days 1-5, 3 cycles)
Assessment at 6 weeks: responders (>PR) → definitive RT; non-responders → total laryngopharyngectomy
Result: 42% larynx preservation; 5-year OS equivalent to surgery arm (~35%)
Conclusion: Survival equivalent to surgery when early salvage is performed; larynx preservation feasible in selected patients

10.2 GORTEC Protocol - Induction TPF vs PF

Docetaxel + Cisplatin + 5-FU (TPF) vs Cisplatin + 5-FU (PF) induction
TPF produces higher response rates and better larynx preservation
TPF is now preferred induction regimen when induction approach is used

10.3 Concurrent Chemoradiotherapy (CCRT)

Cisplatin 100 mg/m2 every 3 weeks x 3 cycles with standard fractionation RT (66-70 Gy)
MACH-NC meta-analysis (nearly 20,000 patients, 100 trials): 6.5% improvement in 5-year OS with concomitant CRT over RT alone
For hypopharynx specifically: 4% benefit - less than oral cavity (8.9%) or oropharynx (8.1%) but statistically significant
Concurrent CRT superior to adjuvant or induction chemotherapy sequencing
Cetuximab (EGFR antibody) + RT: Bonner trial showed improved LRC and OS; alternative for cisplatin-ineligible patients
CCRT: laryngectomy-free survival superior to sequential CRT (HR 0.28; Panda et al., 2022)

10.4 Surgery vs CCRT - 2024 Meta-analysis Data

Critical Evidence: A 2024 systematic review and meta-analysis (Tsai et al., J Otolaryngol Head Neck Surg, PMID 39468833; 8 studies, n=1619) found that upfront surgery was significantly associated with better overall survival (aHR 0.66, 95% CI 0.57-0.78) and disease-free survival (aHR 0.75, 95% CI 0.63-0.90) compared to upfront CCRT. This finding held true for Stage III/IV disease.

11. RECONSTRUCTION AFTER TOTAL LARYNGOPHARYNGECTOMY

Flap	Advantages	Disadvantages
Pectoralis Major Myocutaneous Flap (PMMF)	Reliable, no microsurgery needed, good bulk, low donor site morbidity	Patch repair only (not circumferential); limited reach; bulky in women
Free Radial Forearm Fasciocutaneous Flap	Thin, pliable, excellent for partial defects, sensate option	Circumferential only if tubed; limited volume
Free Jejunal Flap	Gold standard for circumferential defects; peristalsis aids swallowing; good blood supply	Requires laparotomy, bowel complications risk; monitoring difficult; noisy swallowing
Gastric Pull-Up (Gastric Transposition)	Best for cervical oesophageal involvement; single anastomosis	Major abdominal surgery; aspiration risk; high mortality (~5%); anastomotic leak
Anterolateral Thigh Flap (ALT)	Versatile, good volume, thin or thick, long pedicle	Variable perforator anatomy; secondary donor site

Recent Evidence (2025): Mattioli et al. (Acta Otorhinolaryngol Ital, PMID 40400380) confirmed that positive surgical margins are a strong independent predictor of local recurrence and worse overall survival. Zero tolerance for positive margins at primary resection remains the gold standard. Intraoperative frozen section analysis of all margins is mandatory.

11.1 Voice Rehabilitation

Tracheoesophageal puncture (TEP) + voice prosthesis: gold standard for voice rehabilitation post-laryngectomy
Primary TEP (at time of surgery): preferred when feasible
Secondary TEP: performed post-healing if primary not done
Oesophageal speech: training by SLT; 20-30% achieve functional speech
Electrolarynx (external vibrator): immediate communication post-surgery

12. RADIOTHERAPY & CHEMOTHERAPY PROTOCOLS

12.1 Radiotherapy Techniques

Technique	Details
IMRT (Intensity Modulated RT)	Standard of care for definitive or adjuvant RT. Allows dose escalation to tumour while sparing parotids, spinal cord, mandible
Conventional Fractionation	66-70 Gy in 33-35 fractions (2 Gy/fraction) for definitive RT
Accelerated / Hyperfractionation	CHART, DAHANCA protocols - improved locoregional control; increased mucositis
Adjuvant/Postoperative RT	60-66 Gy; begins 4-6 weeks post-surgery. Mandated for: positive/close margins, ENE, multiple nodes, T3/T4, perineural/lymphovascular invasion
Conventional 2D RT	Used when IMRT not available; less precise sparing of OARs

Dose volumes:

GTVp (primary) + GTVn (nodes): 66-70 Gy
CTVhigh risk (subclinical): 60-63 Gy
CTVlow risk (elective neck): 50-54 Gy

12.2 Chemotherapy Regimens

Setting	Regimen	Evidence
Concurrent with RT (first-line)	Cisplatin 100 mg/m2 q3w x 3 cycles OR Cisplatin 40 mg/m2 weekly	MACH-NC: 6.5% OS benefit; standard of care
Cetuximab + RT	Cetuximab 400 mg/m2 loading then 250 mg/m2 weekly (Bonner protocol)	Improved LRC and OS over RT alone; alternative to cisplatin
Induction	TPF: Docetaxel 75 mg/m2 + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day Days 1-5 (3 cycles)	GORTEC: superior response vs PF; preferred induction
Recurrent/Metastatic (first-line)	Platinum + 5-FU + Cetuximab (EXTREME protocol) OR Pembrolizumab ± Platinum/5-FU (KEYNOTE-048)	PD-L1 CPS≥20: pembrolizumab monotherapy; CPS≥1: pembro + chemo
Second-line	Weekly paclitaxel, capecitabine, methotrexate, docetaxel	Response rates 15-30%; palliative intent
Immunotherapy	Pembrolizumab, Nivolumab (CheckMate-141) for R/M disease	Nivolumab: improved OS vs standard (7.5 vs 5.1 months)

13. PROGNOSIS

Hypopharyngeal carcinoma carries the worst prognosis of all head and neck cancers. This is primarily attributable to late presentation (>75% Stage III/IV), the biology of the primary tumour (submucosal spread, high nodal metastasis rate), and the physiological consequences of treatment on swallowing and airway.

Stage	Prognosis
Stage I	Excellent - rarely diagnosed at this stage
Stage II	Favourable when N0 and organ preservation feasible
Stage III	Single nodal disease; organ-preservation considerations
Stage IVA	Resectable but advanced; outcomes depend on margin status, ENE
Stage IVB	Unresectable; CCRT with palliative intent; poor outcome
Stage IVC	Distant metastasis; systemic therapy; median OS ~10-12 months

13.1 Poor Prognostic Factors

Advanced T stage (T3-T4) at presentation
Nodal metastasis - especially bilateral, ENE positive, N3 disease
Piriform sinus apex involvement (poor endoscopic and CT visualisation → understaging)
Prevertebral fascia invasion (T4b) - renders disease unresectable
Positive or close resection margins
Lymphovascular and perineural invasion
Submucosal spread (upstages ~60% of cases)
Poor performance status (ECOG >2)
Active heavy smoking and alcohol use
Secondary synchronous primary (5-10%)
Hypopharyngeal location per se (vs larynx or oropharynx)

Evidence (2024): Cooke et al. (Head Neck, PMID 38716810) found that salvage total laryngopharyngectomy after CCRT failure is associated with significant morbidity but can achieve 5-year OS of 30-45% when performed early. Pharyngocutaneous fistula is the most common major complication (15-30%). Prior CCRT significantly increases perioperative morbidity of salvage surgery.

14. RECENT ADVANCES & EVIDENCE-BASED UPDATES

14.1 Immunotherapy in Advanced HPSCC

Pembrolizumab (anti-PD-1) - KEYNOTE-048 (2019): first-line for R/M HNC including HPSCC
- PD-L1 CPS ≥20: pembrolizumab monotherapy superior to EXTREME
- PD-L1 CPS ≥1: pembrolizumab + chemotherapy improves OS vs EXTREME regimen
Nivolumab - CheckMate-141: improved OS in platinum-refractory R/M HNC (7.5 vs 5.1 months)
PD-L1 testing now standard before initiating treatment for R/M disease

14.2 Transoral Robotic Surgery (TORS) - Emerging Role

Growing evidence for T1-T2 HPSCC in experienced centres
Advantages: 3D vision, 10x magnification, wristed instruments, no fulcrum effect
Comparable oncological outcomes with superior functional results vs open surgery for early lesions

14.3 Diffusion-Weighted MRI (DWI)

Evidence (2024): Parsaei et al. (Eur J Radiol, PMID 38878501) showed that DWI has high diagnostic accuracy for hypopharyngeal/laryngeal carcinoma staging and can predict early treatment response to CRT. ADC (apparent diffusion coefficient) values are inversely correlated with tumour aggressiveness.

14.4 Proton Beam Therapy

Dosimetric advantages over IMRT - reduced dose to salivary glands, mandible, spinal cord
Particularly advantageous for re-irradiation of recurrent disease
Randomised evidence accumulating; not yet standard of care in most centres

14.5 Targeted Therapy & Molecular Markers

EGFR overexpression: present in >80% of HPSCC; target for cetuximab and panitumumab
VEGFR inhibitors (bevacizumab): studied in combination with CRT; toxicity concerns
PI3K/AKT/mTOR pathway alterations: under investigation as therapeutic targets
Liquid biopsy / ctDNA: emerging for monitoring treatment response and early recurrence detection

14.6 Photodynamic Therapy (PDT)

Applicable in early superficial lesions and carcinoma-in-situ
Uses photosensitiser + light to generate reactive oxygen species - selective tumour cell kill
Role limited; mostly adjunctive or for patients unfit for surgery/RT

14.7 Nutritional and Quality of Life Outcomes

Dysphagia is a major long-term morbidity - present in >50% post-CRT; intensive SLT input required
Prophylactic PEG insertion before CRT reduces hospitalisation from acute malnutrition
FEES (Fiberoptic Endoscopic Evaluation of Swallowing) and videofluoroscopy: essential post-treatment assessment tools
Patient-reported outcomes (PRO) increasingly recognised as treatment endpoints in clinical trials

REFERENCES

Flint PW, Francis HW, Haughey BH et al. Cummings Otolaryngology Head and Neck Surgery, 7th Edition. Elsevier, 2021.
Watkinson JC, Clarke RW (Eds). Scott-Brown's Otorhinolaryngology Head & Neck Surgery, 8th Edition. CRC Press / Taylor & Francis.
Lee KJ. Essential Otolaryngology: Head & Neck Surgery, 11th Edition. McGraw-Hill, 2022.
Glasscock ME, Shambaugh GE. Surgery of the Ear, 5th Edition. WB Saunders.
Panda S et al. Treatment options for resectable hypopharyngeal SCC: A systematic review and meta-analysis of RCTs. PLoS One 2022. PMID: 36445884.
Tsai TY et al. Upfront Surgery Versus Upfront CCRT in HPSCC: A Systematic Review and Meta-Analysis. J Otolaryngol Head Neck Surg 2024. PMID: 39468833.
Cooke PV et al. Salvage surgery for recurrent or residual hypopharyngeal SCC: A systematic review. Head Neck 2024. PMID: 38716810.
Parsaei M et al. Clinical utility of DWI in diagnosing and predicting treatment response of laryngeal and hypopharyngeal carcinoma. Eur J Radiol 2024. PMID: 38878501.
Deuss E et al. Nodal metastasis and value of neck dissection in T1/T2 hypopharyngeal carcinomas. Laryngorhinootologie 2024. PMID: 38830380.
Mattioli F et al. The impact of resection margins in hypopharyngeal surgery: a systematic review and meta-analysis. Acta Otorhinolaryngol Ital 2025. PMID: 40400380.
Saraniti C, Barbara V. Thunderbeat: a new step forward in transoral surgery. Eur Arch Otorhinolaryngol 2023. PMID: 37014427.
MACH-NC Collaborative Group. Chemotherapy in Head and Neck Cancer: Updated Meta-Analysis. J Clin Oncol 2011.
Burtness B et al. KEYNOTE-048: Pembrolizumab for R/M HNSCC. Lancet 2019;394(10212):1915-1928.
Ferris RL et al. CheckMate 141: Nivolumab for R/M Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-1867.
AJCC Cancer Staging Manual, 8th Edition. American Joint Committee on Cancer, 2017.

That's the complete content of your exam answer. You can select all and copy it from here. Once your download issue resolves, the PDF is still available at the link above.

This is a shared conversation. Sign in to Orris to start your own chat.